Inside the Orforglipron Phase 3 Trial: What We Know So Far
With growing demand for effective, accessible weight loss treatments, the spotlight is firmly on Orforglipron — a promising new oral GLP-1 receptor agonist currently in its Phase 3 trial stage.
Developed by Eli Lilly, Orforglipron is poised to become the first non-injectable GLP-1 medication for weight loss. But how is it performing in trials, and what can we expect next?
Let’s break it down.
What Is the Orforglipron Phase 3 Trial?
The Phase 3 trial is the final hurdle before a medication is submitted for regulatory approval. This large-scale study evaluates how well Orforglipron works, how safe it is, and how it compares to other treatments — particularly GLP-1 injectables like Wegovy and Mounjaro.
So far, the results are looking impressive:
- Participants taking higher doses of Orforglipron experienced significant weight loss — up to 14.7% body weight reduction.
- Patients with type 2 diabetes also saw meaningful drops in HbA1c levels, indicating improved blood sugar control.
- The side effects, mostly gastrointestinal (nausea, diarrhoea, etc.), were similar to other GLP-1 medications.
The big bonus? It’s all happening without injections.
Orforglipron Approval Timeline: What’s Next?
Based on the trial’s progression, Eli Lilly expects to apply for approval by late 2025. If all goes to plan, Orforglipron could be approved in the UK by 2026 — potentially offering a more convenient solution for people who don’t want injections.
This would make Orforglipron the first daily oral GLP-1 weight loss medication of its kind — a major development in the fight against obesity and related health conditions.
Can’t Wait? MedCare Health Clinic Can Help Now
While Orforglipron makes its way through trials, you don’t have to wait to begin your weight loss journey. At MedCare Health Clinic, we offer fast-track access to two powerful alternatives:
- Wegovy – a weekly semaglutide injection that helps curb appetite and reduce body fat
- Mounjaro – a newer injectable combining GLP-1 and GIP actions, with even stronger trial results
Both options are available now, with online consultations and secure delivery throughout the UK.
Why Choose MedCare Health Clinic?
At MedCare, we provide:
- Compassionate, expert weight loss consultations
- Personalised prescribing and support
- Flexible appointment options
- Early updates on new treatments like Orforglipron
Whether you’re preparing for the future or ready to take action now, we’re here to support your goals.
Final Thoughts
The Orforglipron Phase 3 trial is delivering strong, promising results — but with approval still months away, there’s no need to delay your progress.
👉 Take control today with MedCare Health Clinic — and be first in line when Orforglipron becomes available.